MagForce AG

MagForce AG: Agreement in principle on the sale of business operations

MagForce AG Decides to Delist its Shares

MagForce AG: Opening of Insolvency Proceedings

MagForce AG: Provisional insolvency administrator appointed by the court

MagForce AG: Application for the Opening of Insolvency Proceedings

MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights

MagForce AG issues Bearer Notes with a total Volume of up to EUR 3.5 Million to Lansdowne Investment Company Cyprus Limited

MagForce AG: MagForce USA, Inc. receives Payment Code Approval by the American Medical Association for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

MagForce AG extends EUR 5.0 million Convertible Notes agreement with Lansdowne Investment Company Cyprus Limited and issues additional Convertible Notes in the amount of EUR 2.0 million

MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval

MagForce AG: MagForce USA, Inc. has Received FDA’s Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Ther

MagForce AG: MagForce USA, Inc. has Received FDA’s Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Ther

MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights

MagForce AG: MagForce USA, Inc. has Received FDA’s Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

MagForce AG and CHIP Hospital Málaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain agForce AG:

MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board

MagForce AG Publishes Financial Results for the Year 2020 and Operative Highlights

MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications

MagForce AG Announces Additional Supportive Data from Stage 2a of its Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System

MagForce AG enters into an Agreement with Apeiron Investment Group Ltd. to issue Convertible Notes in the total amount of EUR 2.5 million

MagForce AG: MagForce USA, Inc. Announces Completion of Patient Treatment in Stage 2a of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System

MagForce AG: MagForce USA, Inc. Announces Completion of Patient Treatment in Stage 2a of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System

DGAP-DD: MagForce AG english

MagForce AG Successfully Completes Private Placement of New Shares

MagForce AG Successfully Places 1,165 Million New Shares Through Cash Capital Increase with Gross Proceeds of approx. 4.7 Million EUR

MagForce AG Launches Capital Increase with Exclusion of Subscription Rights from Authorized Capital

MagForce AG Announces Opening of New NanoTherm Treatment Center for Brain Tumor Patients at Mühlhausen Hufeland Clinic in Thuringia, Germany

MagForce AG Publishes Financial Results for the First Half of 2020 and Operative Highlights

MagForce AG: ‘NanoTherm School’ successfully enters the third round with ‘Module B – Part II’

MagForce AG Publishes Shareholder Letter